Horizon Pharma (HZNP) Upgraded to “B-” at TheStreet

TheStreet upgraded shares of Horizon Pharma (NASDAQ:HZNP) from a c rating to a b- rating in a report released on Tuesday morning.

HZNP has been the subject of a number of other research reports. Piper Jaffray Companies set a $25.00 target price on Horizon Pharma and gave the company a buy rating in a research note on Monday, September 17th. BidaskClub cut Horizon Pharma from a strong-buy rating to a buy rating in a research note on Tuesday, September 18th. Mizuho restated a buy rating and issued a $25.00 target price on shares of Horizon Pharma in a research note on Wednesday, November 7th. Morgan Stanley raised their target price on Horizon Pharma from $16.00 to $24.00 and gave the company an equal weight rating in a research note on Friday, August 17th. Finally, Goldman Sachs Group set a $26.00 target price on Horizon Pharma and gave the company a buy rating in a research note on Thursday, October 4th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $23.25.

Shares of HZNP stock opened at $21.15 on Tuesday. The company has a market capitalization of $3.50 billion, a PE ratio of 17.92, a price-to-earnings-growth ratio of 1.38 and a beta of 1.29. Horizon Pharma has a fifty-two week low of $12.55 and a fifty-two week high of $23.38. The company has a debt-to-equity ratio of 2.06, a quick ratio of 1.86 and a current ratio of 1.94.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.15. The firm had revenue of $325.30 million for the quarter, compared to analyst estimates of $311.84 million. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS. Research analysts forecast that Horizon Pharma will post 1.3 earnings per share for the current year.

In other Horizon Pharma news, Chairman Timothy P. Walbert sold 408,347 shares of Horizon Pharma stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the completion of the transaction, the chairman now owns 650,404 shares in the company, valued at $14,009,702.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.90% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. First Quadrant L P CA raised its stake in Horizon Pharma by 189.1% during the third quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 4,001 shares during the last quarter. Rehmann Capital Advisory Group raised its stake in Horizon Pharma by 2,162.2% during the third quarter. Rehmann Capital Advisory Group now owns 7,420 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 7,092 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new position in Horizon Pharma during the second quarter valued at $172,000. Ibex Investors LLC purchased a new position in Horizon Pharma during the third quarter valued at $211,000. Finally, Strs Ohio raised its stake in Horizon Pharma by 74.2% during the second quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 4,600 shares during the last quarter. Institutional investors and hedge funds own 88.64% of the company’s stock.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Read More: What is Cost of Debt?

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply